Drugs / MGB-BP-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02518607 | Jul → Nov 2015 | — | MGB Biopharma Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03824795 Comparator | Feb 2019 → Apr 2020 | Clostridium difficile colitis | MGB Biopharma Limited | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGB-BP-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03824795 ↗ |
| Known as | J2.725.402K | ChEMBL registry synonym — accepted as the source's own label CHEMBL236345 ↗ |
| Modality | Small molecule | — CHEMBL236345 ↗ |
| Route | Oral | “oral MGB-BP-3” NCT02518607 ↗ |